JPMorgan Healthcare finishes for another year - what were your special JPMemories? Read ours below 🤯 1. Our CEO @ Thomas Clozel’s journey from hell: 29 hours ✈️ halfway round the world to make his first meetings. He just wouldn’t quit… 2. THAT banner. Double-O-wkin - the agent cancer never saw coming. Nor did SF. 3. Fitness for breakfast. 💪 4. Absolutely gorgeous weather?! Unheard of. 5. Owkin, NVIDIA and Anthropic. ❤️ 6. A request to hire a scooter to get to meetings on time that was - thankfully - denied. Not looking at anyone in particular Thomas Clozel. 7. Balloons that didn’t quite live up to the design the marketing team were promised. 🫠 8. 10 press interviews. 9. 115 meetings (that we know of). 10. 3 Last minute podcast sessions 🎤 . Grabbing the big names to hear their take on Agentic AI in healthcare. 11. 98 cups of ☕ drunk (that the team admitted to). 12. 1193 mentions of Agentic AI (and that’s just Thomas Clozel). 13. 32 thousand mentions of Artificial Super Intelligence. 14. “Sorry I’m late” said 303 times. What’s your best memory? In the comments please 👇
OWKIN
Technology, Information and Internet
New York, NY 60,454 followers
We create the first closed-loop AI generative biology company to create the new standard of biology reasoning
About us
Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.
- Website
-
https://www.owkin.com
External link for OWKIN
- Industry
- Technology, Information and Internet
- Company size
- 201-500 employees
- Headquarters
- New York, NY
- Type
- Privately Held
- Founded
- 2016
- Specialties
- artificial intelligence, omics technology, oncology, drug discovery, medical research, biomedical images, real-world data, clinical data, federated learning, clinical tools, digital pathology, healthcare, diagnostic solutions, and data science
Locations
Employees at OWKIN
Updates
-
✈️ No rest after #JPM! We’re heading straight to Davos 🇨🇭 Our CEO and Co-founder Thomas Clozel will be in Davos to discuss Owkin’s new agentic infrastructure, laying the groundwork for our goal of achieving Biological Artificial Super Intelligence (BASI). That’s AI that can reason across the full complexity of biological systems to enable Owkin’s approach: automating scientific research and discovery through our AI scientist, advancing causal understanding of biology.
-
-
💬 Great conversation with BiotechTV during #JPM Our CEO and co-founder Thomas Clozel spoke about our recent collaborations with NVIDIA and Anthropic, and what they mean for bringing agentic AI into drug discovery and development. Hear Thomas explain how our Pathology Explorer agent and our biological reasoning model OwkinZero all power K Pro - and how its essential to build this all on patient data. Read Owkin’s press release: https://lnkd.in/dGFwX23Q
𝐒𝐅 𝐇𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐖𝐞𝐞𝐤: OWKIN struck new deals with NVIDIA and Anthropic this week to bring agentic AI into drug discovery and disease research. CEO Thomas Clozel explains how this will help scientists reason across biology, pathology and patient data rather than analyze each piece in isolation. BiotechTV’s coverage of SF Healthcare Week is brought to you by HSBC Innovation Banking. BiotechTV is brought to you by: Mispro | Breakthrough Properties | HSBC Innovation Banking | Allucent | NYSE | Klein Hersh | Savills North America | Genezen | Orchestra | Evaluate Ltd
-
💥 #JPM mornings don’t usually start like this Yesterday, before the inboxes exploded and the agendas filled up, the Owkin crew (with our friends at AWS) chose movement over meetings. Early alarms. Big energy. 🥊 Gloves on 🔥 Heart rates up 🧘 Focus locked in ☕ Then the reward: a refuelling breakfast, great coffee, and some much-loved Owkin goodies It was the perfect way to connect - clear heads, good conversations, and a strong start to a very busy week. Huge thanks to everyone who joined us (and blew away the jet lag at 6:30am 🙌).
-
-
🚀 Owkin announces partnership with Anthropic during JPM week. Owkin unveils its Pathology Explorer agent, part of the K Pro community of biological AI agents, as part of Anthropic’s Claude for Healthcare & Life Sciences. 🔬 Pathology Explorer is trained primarily on multimodal patient data and made accessible via the Model Context Protocol (MCP) - bringing highly specialized, state-of-the-art agentic AI directly into healthcare and life sciences workflows. The agent enables spatially aware analysis of tissue images to identify cells and tissues, analyze tumors and inflammation, and extract biomarkers that support cohort-level survival analysis—accelerating drug discovery, clinical trial design, and digital diagnostics. Through Owkin’s agentic infrastructure for Biology, healthcare organizations, pharma companies, and researchers can access advanced pathology intelligence directly within Claude, without system overhauls. Read the press release: https://lnkd.in/dwp7fu7x
-
🤖 Today we launch our agentic infrastructure for biology. We’re going to make our best-in-class agentic AI interoperable - making it available throughout the healthcare ecosystem to quickly and efficiently assist in research, analysis and clinical trial decision making, from their platform of choice. Our new agentic infrastructure sets the groundwork for Owkin's goal of achieving Biological Artificial Super Intelligence (BASI) - AI that can reason across the full complexity of biological systems. Owkin’s strategy is to automate scientific research and discovery through Owkin’s AI scientist to eventually understand causal biology and reach BASI. Read more in our press release here: https://lnkd.in/dGFwX23Q
-
📢 We are announcing our new collaboration with NVIDIA to enhance OwkinZero, Owkin's biological large reasoning model. The collaboration will leverage NVIDIA's advanced AI computing ecosystem, including the Nemotron family of open models and the NVIDIA NeMo framework to improve the performance, scalability, guardrails, and robustness of Owkin's biological reasoning capabilities to accelerate future breakthroughs in drug discovery and development. This marks Owkin's first collaboration with NVIDIA and represents a significant milestone in building the agentic infrastructure necessary for achieving Biological Artificial Super Intelligence (BASI). You can read more in our press release here: https://lnkd.in/dArMp6WX
-
-
✈️ Our CEO Thomas Clozel and the Owkin team are bringing biological artificial superintelligence to San Francisco during the J.P. Morgan Annual Healthcare Conference. We meet, we greet and we try to snatch a moment to eat amid all the appointments! It’s a hugely exciting time for AI in healthcare and pharmaceuticals. It feels like the future is getting closer and closer and we’re loving the ride (and look out for some exciting Owkin news to go with all of it)! Find out about what we’re up to here: https://lnkd.in/dGFwX23Q
-
🔑 Les Echos publishes new article featuring Owkin as a key AI partner for pharmaceutical R&D. The article highlights how AI and Pharma collaborations are reshaping drug discovery - helping de-risk development, reduce costs, and accelerate innovation. Through a non-exclusive partnership model, Owkin has worked with leading pharma groups including Sanofi, Bristol Myers Squibb, MSD, and AstraZeneca, combining advanced AI with pharmaceutical know-how to explore new therapeutic approaches. Read the article here: https://lnkd.in/exKktQir
-